Robotic Hepatic Artery Infusion Pump Placement after Recurrent Colorectal Liver Metastasis following Open Left Hemihepatectomy.

Ann Surg OncolMay 20, 2026 (epub)
Case ReportGeneral SurgeryOncology (Medical)Nuclear Medicine

Bhavya Bansal, Sharona Ross, Iswanto Sucandy

✦ AI-curated · Sources linked

Case in brief

A 62-year-old man with recurrent multifocal liver metastases from rectal cancer underwent robotic hepatic artery infusion pump placement following prior open left hemihepatectomy. Initial imaging revealed multiple unresectable lesions in the remnant liver. The procedure was completed in 150 minutes with minimal blood loss, and the patient was discharged on postoperative day 3 without complications. Postoperative imaging confirmed uniform hepatic perfusion.

Diagnostic / clinical pearl

Robotic placement of a hepatic artery infusion pump is a safe and feasible option even in patients with a history of open abdominal surgeries.

Source

PubMed · PMID 42156621

Published in Ann Surg Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.